Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Main Inclusion Criteria:

• Patients diagnosed with IPF who meet all criteria from (1) through (4) during thecourse of IPF

• (1)Unexplained development or worsening of dyspnea within 1 month during the course ofIPF

• (2)Finding of new, bilateral ground glass opacities and/or consolidation on HRCT

• (3)No apparent Pulmonary infections, pneumothorax, malignant tumors, pulmonaryembolism, or left heart failure

• (4)A decrease* in PaO2 of ≥10 mmHg or SpO2 of ≥4% under the same conditions comparedwith the level at the previous measurements

• (*) In cases where no PaO2 or SpO2 test values under the same conditions areavailable, a patient with a P/F ratio ≤300 in the current episode of acuteexacerbation is considered to have met criterion (4)

• Aged 40 years or older and no older than 85 years at the time of informed consent witheither sex

Main Exclusion Criteria:

• Have intracranial hemorrhage, pulmonary hemorrhage, gastrointestinal bleeding (continued hematemesis, bloody discharge, gastrointestinal ulcer-induced hemorrhage)

• Have a history of cerebrovascular disorder (e.g., cerebral hemorrhage or cerebralinfarction) within 52 weeks (364 days) before informed consent

• Patients for whom the completion of hemostatic treatment has not been confirmed afterundergoing surgery of the central nervous system or after trauma

• Have a high risk for fatal or life-threatening hemorrhage

• Patients with malignant tumors

• Have acute exacerbation attributable to drug induced pulmonary disorder, after surgeryfor malignant tumors, chemotherapy, or radiation therapy

• Have acute exacerbation due to a thoracic surgical procedure (including thoracoscopiclung biopsy)

• Have a history of acute exacerbation of IPF

• Receiving mechanical ventilation through intratracheal intubation

• Patients who are pregnant or nursing, or who may be pregnant

• Patients with a platelet count less than 100,000/uL at the time of enrollment

• Patients with severe renal (serum Cr: ≥4 mg/dL) or hepatic (AST/ALT: ≥500 IU/L orT-Bil: ≥10 mg/dL) dysfunction

• Have been administered a commercially available thrombomodulin alfa (recombinant )(Recomodulin® for Intravenous Injection 12800) within 30 days before the start ofinvestigational product administration

• Have a history of hypersensitivity for investigational product